comparemela.com

Latest Breaking News On - Alexis peyroles - Page 5 : comparemela.com

OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting

OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces the procedures for participating to the Combined General Meeting, to be held on June 24, 2021 at 2:30 p.m. CET. As indicated in the press release dated May 19, 2021, the Combined General Meeting of June 24, 2021, will be held by live webcast, without the physical presence of shareholders or other persons usually eligible to attend pursuant to the provisions of the the order published on 25 March 2020 extended and amended by order no. 2020-1497 of 2 December 2020, decree no. 2020-418 of 10 April 2020 extended and amended by decree no. 2020-1614 of 18 December 2020 and decree no. 2021-255 of 9 March 2021.

OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi in Combination with Opdivo (nivolumab) in Non-Small Cell Lung Cancer

First patient dosed with multi-variant second-generation COVID-19 vaccine

First patient dosed with multi-variant second-generation COVID-19 vaccine
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

(1) First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated immune response against 11 different proteins of SARS-CoV-2 virus to provide a long-term cellular immunity with memory T cells. Phase 1 study expected to read-out in September 2021. Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT. This Phase 1 clinical trial is evaluating the safety, reactogenicity and immunogenicity of two dose regimen of CoVepiT in 48 healthy adult volunteers, previously vaccinated or not by an authorized COVID-19 vaccine (NCT04885361).

▷🥇 En la lucha contra las variantes de Covid-19, algunas empresas se dirigen a los golpes de células T

▷🥇 En la lucha contra las variantes de Covid-19, algunas empresas se dirigen a los golpes de células T
latarde.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from latarde.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.